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Abstract: This paper highlights the low levels of vaccine coverage and high levels of reported 16 
vaccination hesitancy in Yerevan, Armenia that present profound challenges to the control of 17 
disease through routine vaccination programmes. We draw on investigations of hesitancy towards 18 
the introduction of new vaccines, using the Human Papillomavirus (HPV) vaccine Gardasil as a case 19 
study, to interrogate underlying challenges to vaccine acceptance. We analyse primary data from 20 
the introduction of Gardasil, first used in Armenia in 2017, to investigate how levels of medical 21 
knowledge amongst physicians in 20 health facilities in Yerevan, Armenia regarding vaccine 22 
science, influence attitudes towards the introduction a newly developed vaccine. A questionnaire- 23 
based cross-sectional study was completed by 348 physicians between December 2017 and 24 
September 2018. The responding physicians displayed a respectable level of knowledge and 25 
awareness regarding vaccination with respect to some characteristics (e.g. more than 81% knew that 26 
HPV infection was commonly asymptomatic, 73% knew that HPV infection was implicated in most 27 
cervical cancers and 87% knew that cervical cancer is the most prevalent cancer amongst women) 28 
but low knowledge and poor understanding of other key issues such as the age at which women 29 
were most likely to develop cervical cancer (only 15% answered correctly); whether or not the 30 
vaccine should be administered to people who had already been infected (27% answered correctly) 31 
and whether sexually-active young people should be treated for infection before vaccination (26% 32 
answered correctly). The study suggests that drivers of vaccine hesitancy are complex and may not 33 
be consistent from vaccine to vaccine. The Armenian healthcare sector may need to provide 34 
additional training, awareness-raising and educational activities alongside the introduction of new 35 
vaccines to improve understanding of, and trust in, vaccination programmes. 36 
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 38 
1. Introduction 39 
Armenia has consistently displayed lower levels of vaccine confidence than 40 
surrounding countries and compared with Europe as a whole [1,2,3], with Armenians 41 
showing low levels of trust in vaccines as safe, effective and/or important [1]. This has 42 
significant implications for control and prevention of vaccine-controllable diseases and 43 
presents a challenge in that the frequency of novel diseases, for which new vaccines will 44 
need to be developed, is predicted to increase during the 21st century [4], risking further 45 
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pandemics such as that caused by COVID-19 [5]. In this paper, we use the introduction of 46 
the HPV vaccine Gardasil in Yereven, Armenia as a case study for understanding vaccine 47 
hesitancy in Armenia more broadly, particularly with regard to the introduction of new 48 
vaccines, and for shedding light on some key underlying reasons for hesitancy. A new 49 
national vaccination programme for human papillomavirus (HPV) has been available 50 
since 2017 but coverage in Armenia is low (10% in the target population in 2020; compared 51 
with 84% in the UK, for example [6]). We use this to identify potential inventions that may 52 
improve vaccine acceptance and confidence and thus enhance the uptake of vaccines for 53 
HPV and which may be generalizable to other diseases, using the HPV vaccine to 54 
conceptualise vaccine hesitancy in Armenia. HPV thus offers a case study that may inform 55 
the roll-out of other national vaccination programmes. The primary data collection has 56 
been reviewed with reference to, two recent market research polls that have interrogated 57 
vaccine hesitancy in Armenia [7,8]. 58 
Human papillomaviruses (HPVs) are a group of viruses belonging to the family of 59 
Papillomaviridae that affect epithelial tissue, the layer or layers of cells that form the 60 
covering of most internal and external surfaces of the body and its organs. More than 150 61 
types of HPV have been identified [9]. In women, HPV infection may cause cervical, 62 
vaginal, vulvar, anal, and oropharyngeal cancers; in males, it may cause anal, penile, and 63 
oropharyngeal cancers [10,11,12]. 64 
Invasive cervical cancer (ICC) is one of the leading causes of cancer in women and, 65 
according to 2018 global estimates, results in approximately 570,000 new cases and 311,000 66 
deaths annually [13]. In the United States, around 4,000 women die from cervical cancer 67 
each year, with African Americans and women from poorer backgrounds having a much 68 
higher rate of mortality [14]. Globally, cervical cancer is the fourth most common cancer 69 
among women. The burden faced by low- and middle-income countries is significantly 70 
higher than in high-income regions of the world [15]. The estimated age-standardised 71 
incidence of cervical cancer in 2018 averaged 13.1 per 100,000 women globally but varied 72 
from less than 2 up to 75 per 100,000 women [13] depending on the country. 73 
In Armenia, the cumulative incidence rate of ICC has increased from 9.5 (1985) to 74 
16.6 (2017) per 100,000 women. Annually, about 120-130 women die from cervical cancer 75 
in Armenia (7.4/100,000 in 2016). About 50% of women with ICC are not diagnosed until 76 
the third and fourth stages of the cancer when the treatment outcome is significantly less 77 
certain [16,17]. 78 
Currently, there are three HPV vaccines available: bivalent (HPV 16 and 18), 79 
quadrivalent (HPV 6,11,16, and 18), and 9-valent (6,11,16,18,31,33,45,52, and 58) which can 80 
protect against up to nine of the most prevalent HPV genotypes associated with cancer 81 
and genital warts [18]. Of these, the quadrivalent is the most common in Armenia. 82 
Globally, HPV vaccines have been extremely successful from both a scientific and clinical 83 
perspective. There is strong evidence of population-level impact on the circulation of HPV 84 
infection, incidence of high-grade cervical cancer and cases of genital warts following the 85 
introduction of national vaccination programmes [19,20].  86 
Despite recommendation for routine HPV vaccinations from the World Health 87 
Organization (WHO), some countries nevertheless remain hesitant about vaccinating 88 
their young people against HPV [21]. Armenia is one of these, and the vaccine hesitancy 89 
shown with regard to HPV vaccination provides warnings of challenges that may also 90 
hinder other vaccination programmes and thus the management of other vaccine- 91 
controllable diseases [22]. 92 
Since the quadrivalent vaccine Gardasil was introduced in Armenia in December 93 
2017 [23], uptake has been slow, with resistance from the medical community as well as 94 
from the public. A study assessing the knowledge, attitudes and practices (KAP) of 95 
physicians regarding HPV and vaccination against HPV, particularly with Gardasil, in 96 
Yerevan, Armenia, conducted between Dec 2017 and Sep 2018 provides baseline 97 
understandings of some causes of vaccine hesitancy and highlights some issues that may 98 
present similar barriers to the uptake of vaccines developed to combat COVID-19. The 99 
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survey results reveal, in addition, that the term ‘vaccine hesitancy’ needs to be unpacked 100 
further as there are degrees or shades of hesitancy that range from near-acceptance to out- 101 
right rejection. These are important if we are to fully understand the challenges of 102 
introducing a new vaccine to a hesitant population. 103 
2. Materials and Methods  104 
Between December 2017 and September 2018, a questionnaire-based, cross-sectional, 105 
quantitative study was conducted in 20 Armenian healthcare facilities to identify 106 
respondents’ awareness of, and attitudes to, HPV-related cervical cancer and the Gardasil 107 
vaccine. The questionnaire did not contain questions specifically related to practice as this 108 
is known to be sub-optimal; the aim of the study was to determine the reasons why. The 109 
questionnaire was adapted from a survey previously used to determine the knowledge 110 
and attitude of registered nurses towards HPV and HPV vaccines in the USA [24]. This 111 
was considered sufficiently generic to not require amendment to the local context. The 112 
questionnaire was administered to physicians at 20 out of 36 government-run healthcare 113 
facilities, selected at random from those available, in Yerevan; this was the number 114 
required to ensure sufficient staff to return a representative sample size, calculated using 115 
the Estimate-proportion n=z2*pq/d2 formula [25].  116 
The inclusion criteria for the study respondents were fully qualified medical staff 117 
from four medical specialities considered most likely to have direct interaction with HPV- 118 
infected patients or with patients eligible for HPV vaccination: paediatricians, family- 119 
practice doctors, gynaecologists, and oncologists. Exclusion criteria were student doctors, 120 
nurses, residents and doctors from other specialities. This yielded a possible survey size 121 
of 405 physicians across the 20 facilities. Trained researchers from Yerevan State 122 
University School of Public Health visited each of the healthcare facilities included and 123 
personally invited physicians to participate in the study. Of the 405 eligible staff, 385 (95%) 124 
were approached in person to participate (the remaining 20 were not available on any of 125 
the days the researchers visited) of whom 348 (90.3%) gave consent and completed the 126 
survey. The survey was conducted by face-to-face interview in each physician’s usual 127 
place of work. This is above the number required to be considered a representative sample 128 
(Figure 1). 129 
Data were collected on the socio-demographic characteristics of the respondents 130 
(gender, age and length of service within the healthcare profession). The questionnaire 131 
also addressed respondents’ existing knowledge and attitudes across four areas: 1) 132 
Knowledge/Information about HPV; 2) Knowledge/Information about the HPV vaccine; 133 
3) Attitude towards the HPV vaccine; and 4) Attitude towards other vaccines. 134 
Respondents could answer the survey questions ‘True’, ‘False’ or ‘I don’t know’, 135 
numerically coded 1, 2, and 88, respectively. 136 




Figure 1. Flow chart of staff recruitment. 138 
2.1. Statistical analysis 139 
Chi-square analyses were used for the categorical variables which compared the age 140 
groups of respondents, their lengths of experience as doctors, and the fields they 141 
specialised in. For all analyses conducted in the study, an association of p<0.05 was 142 
considered to be statistically significant. Analyses were performed using SPSS software 143 
(Version 16.0).  144 
A hierarchy heatmap on physicians’ knowledge of and attitudes to the HPV vaccine 145 
was constructed using the R statistical programme language package ‘pheatmap’ 146 
(https://www.rdocumentation.org/packages/pheatmap/versions/1.0.12/topics/pheatmap) 147 
based on the percentage of respondents who answered ‘yes’ to a series of questions. 148 
2.2. Multivariate logistic regression analysis 149 
Multivariate logistic regression analysis was performed to determine which factors 150 
affect knowledge of and attitudes to HPV and of HPV vaccine amongst physicians in 151 
Armenia. Using the or_plot function in R package  “finalfit”, nine logistic regression 152 
models and forest trees were constructed to determine the odds ratio (OR) and 95% 153 
confidence intervals (CI) for physicians answering at random: 1) HPV is relatively 154 
uncommon? (false) 2) Almost all cervical cancers are caused by HPV? (true) 3) HPV is 155 
most common in women in their 30s? (true) 4) Cervical cancer is one of the most prevalent 156 
cancers among women (true)? 5) Most people with genital HPV are symptomatic (false)? 157 
6) Genital warts are caused by the same HPV types that cause cervical cancer (false)? 7) 158 
Sexually-active adolescents should be tested before HPV vaccination (false)? 8) HPV 159 
vaccine is available for both males and females (true)? and 9) Men and women who have 160 
been diagnosed with HPV should not be given HPV vaccine (false)? Factors that were 161 
considered in the model were physician speciality, age and experience. 162 
3. Results 163 
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A total of 348 participants (90.3% of those eligible) from the 20 randomly selected 164 
health facilities (from total of 36 health facilities located in Yerevan) completed the survey 165 
and were included in the final analysis (Figure 1).  166 
The respondents were predominantly female (95%), reflecting the demographics of 167 
the professions (paediatricians, family-practice physicians, gynaecologists, and 168 
oncologists). The gender inequality among the respondents (95% female) is not a 169 
limitation of this study: according to recent statistics, in Armenia female doctors are more 170 
likely to specialise in paediatrics, family-practice and gynaecology, hence the high levels 171 
of female respondents in this study. A report published by the Ministry of Health, 172 
Armenia in 2016 shows that 40-60% of physicians were female and of these 91.8% were 173 
paediatricians, family-practice physicians and general practitioners; 95.2% of all 174 
paediatricians were female [26]. As previous studies of vaccine hesitancy either recorded 175 
no significant differences between men and women [27] or have been inconsistent over 176 
which gender is more likely to be vaccine hesitant [28,29], a heavily female survey cohort 177 
is unlikely to influence perceptions of vaccine hesitancy overall, though this should be 178 
tested in future studies if possible. Of those participating in this study, 62% were 179 
paediatricians, 16% family-practice physicians, 13% gynaecologists, and 9% were 180 
oncologists. The age distribution was 29-60+years of age, with 52% between 45 and 59 181 
years old. Two-thirds (67%) had more than 20 years of experience as doctors. 182 
3.1. Knowledge of HPV transmission, symptoms and disease 183 
In response to some questions, study participants displayed strong awareness of the 184 
issues surrounding HPV infection and its related health outcomes, for instance most knew 185 
that cervical cancer is one of the most prevalent types of cancer among women (87.2%), 186 
and nearly three-quarters (73.4%) knew that most cervical cancers are caused by the HPV 187 
virus (Table 1). Awareness of presentation of the disease was also high, with 81% aware 188 
that most people with genital HPV infections are unlikely to display symptoms. 189 
However, 44.4% of the participants were unaware that HPV is a relatively common 190 
sexually transmitted infection, and 29% of respondents were unaware that the vaccine is 191 
available to both females and males. More than half (53.5%) answered that the same types 192 
of HPV that cause genital warts also cause cervical cancer, which is incorrect. Only 27% 193 
of the respondents were aware that both male and female patients diagnosed with HPV 194 
should still be encouraged to receive the vaccine, and only a similar proportion (26%) 195 
knew that sexually-active adolescents do not need to be tested before receiving their HPV 196 
vaccinations. Fewer than two thirds (61%) of physicians knew that the HPV vaccine 197 
consists of recombinant HPV protein.  198 
3.2. Knowledge compared by medical specialism  199 
The proportion of correct answers varied among the physicians according to 200 
speciality, although the differences were not statistically significant overall (p>0.05). A 201 
higher number of correct answers came from paediatricians (65%) than from other groups. 202 
Gynaecologists were more likely than other specialities to answer correctly that HPV 203 
is most common in women in their 30s (OR 0.12, p=0.000824), although as only 40.9% of 204 
gynaecologists answered correctly, knowledge was low over all specialties. 205 
Gynaecologists were, however, more likely to answer incorrectly that genital warts are 206 
caused by the same strains of HPV, with 65.9% giving an incorrect answer compared with 207 
24.6% of paediatricians (OR 2.17 p=0.0246) (Table S1). This suggests that physicians’ level 208 
of knowledge is inconsistent across specialties. 209 
For the other questions, differences between specialities were not statistically 210 
significant, though paediatricians (74.8%) and oncologists (74.2%) returned a higher rate 211 
of correct responses than family practitioners (70.9%) and gynaecologists (68.2%) for the 212 
question, “All common cervical cancers are caused by HPV” (p=0.03). There was no 213 
significant difference between the specialties in their understanding of whether people 214 
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with HPV are likely to be symptomatic (they were equally incorrect) (p=0.187); that 215 
cervical cancer is one of the most common cancers amongst women, which most answered 216 
correctly (p=0.08); and whether or not HPV is a relatively common infection (p=0.643), 217 
which just over half of family physicians, oncologists and paediatricians believed to be 218 
true, and just under half of the gynaecologists (46.5%).   219 
Table 1. Knowledge of HPV of physicians practicing different specialist areas. 220 
Physicians  
Characteristic 






Almost all cervical 
cancers are caused by 
HPV infection. 




Genital warts are caused 
by the same HPV types 
that cause cervical 
cancer. 
 T F  DK T F DK   T F DK   T F DK 
Specialty             
Family physicians 38.9 53.7  7.4 70.9 20 9.1  20.4 75.9 3.7    43.6 43.6 12.8 
Paediatricians 36.9 58.3  4.9 74.8 20 5.2  11.8 80.4 7.8    65.2 24.6 10.1 
Gynaecology 48.8 46.5  4.7 68.2 31.8 0:0  9.1 90.9 0.0    22.7 65.9 11.4 
Oncology 35.5 51.6  12.9 74.2 12.9 12.9  16.7 80 3.3    32.3 58.1 9.7 
Age             
Less than 44 28.4 69.1  2.5 68.3 28.0 3.7  10.1 87.3 2.5    45.0 43.8 11.2 
45 to 59 39.0 55.9  5.1 77.8 18.9 3.3  11.9 82.4 5.7    56.5 33.9 9.6 
Older than 60 48.1 40.7  11.1 68.7 18.1 13.2  18.3 73.2 8.5    54.8 32.1 13.1 
Experience (Years)             
Less than 14 33.8 63.1  3.1 67.7 30.8 1.5  6.2 90.6 3.1    38.5 44.6 16.9 
15 to 19 42.9 57.1  0.0 83.7 14.3 2.0  12.2 87.8 0.0    47.9 50.0 2.1 
More than 20 38.9 52.9  8.1 73.5 18.6 7.9  16.0 76.3 7.7     59.2 30.0 10.8 
T-true; F-false; DK-don’t know. 221 
3.3. Knowledge compared by age and length of professional service  222 
The proportion of correct answers was significantly different across the age groups 223 
(p=0.004). Respondents in the age group 45-59 years old returned a higher rate of correct 224 
answers overall. Physicians in the age group under 44 years old were more likely (69.1%) 225 
to give a correct answer for the question regarding how common HPV is (Table 1) 226 
compared with physicians in age groups 45-59 and over 60 (OR 2.56 and 5.26, p-value 227 
0.023637 and 0.000724 respectfully) (Figure S1). The 45-59 age group were also more likely 228 
to answer correctly that almost all cervical cancers are caused by HPV infection (77.8%) 229 
than those in the lower age group (68.3%, p=0.018) and those over 60. 230 
The proportion of correct answers was significantly different when compared across 231 
the number of years of service. Respondents with 15–19 years of service answered 232 
questions correctly more often (50%) than those who had been in the profession for both 233 
a longer (30%) and a shorter time (44.6%) (p=0.003). This difference may be linked to mid- 234 
career physicians being more likely to still attend courses and to engage in more 235 
educational activities than those nearing the end of their careers, which provides them 236 
with more opportunities for keeping up-to-date with new developments.  237 
3.4. Attitudes towards HPV vaccination 238 
The survey contained six questions that measured confidence or hesitancy to 239 
vaccines in general and the HPV vaccine in particular. The majority of the respondents 240 
(87.7%) supported the national vaccination programme for general childhood vaccination 241 
but fewer than two-thirds (63.8%) agreed that the introduction of the HPV vaccine into 242 
the national vaccination programme was appropriate. More than half (53.3%) expressed 243 
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concern over the efficacy of the HPV vaccine, 61.0% expressed concerns over its safety, 244 
and 58.50% agreed with the statement that the vaccine is “too new and hasn’t been around 245 
long enough”. Just under half (42.9%) agreed with the statement that 13 is too young for 246 
a child to receive the vaccine (Figure 2). 247 
 248 
Figure 2. Hierarchy clustering heatmap showing attitudes to HPV vaccine of physicians from different specialities. 249 
Number in squares indicates the percentage who said yes. 250 
3.5. Support for vaccination by specialty 251 
Different specialties displayed statistically significant (p<0.0001) attitudes to the 252 
introduction of the HPV vaccine into the national vaccination programme: a higher 253 
proportion of paediatricians (75.2%) agreed with it, which was statistically higher than the 254 
other groups (oncologists 57%; family physicians 47% and gynaecologists 36%). The high 255 
likelihood of paediatricians to agree with the need for the HPV vaccination programme is 256 
consistent with a study from Serbia in which nearly two-thirds of the paediatricians were 257 
willing to recommend the vaccine (60.2%) [30]. 258 
The proportion of physicians concerned about side effects of the vaccine (including 259 
the risk of infertility, for which there is no medical evidence) also differed significantly 260 
among different specialties (p < 0.0001), with a higher percentage of family physicians and 261 
gynaecologists showing concern (respectively 76.4% and 79.5%) than paediatricians and 262 
oncologists (52% and 67%). Physicians over 60 years old showed a statistically 263 
significantly different level of concern about efficiency and the side effects than those 264 
under 60 (respectively p=0.003, p=0.002) (Tables 1 and 2). 265 
 266 
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Table 2. Knowledge of HPV: Comparison between physicians practicing different specialist areas. 267 
True/False Statement % Correct Total 










HPV is relatively uncommon. 55.6 53.7 58.3 46.5 51.6 5.653 0.643 
Almost all cervical cancers are caused by HPV. 73.4 70.9 74.8 68.2 74.2 18.436 0.03 
HPV is most common in women in their 30s. 15.1 10.9 9.5 40.9 22.6 36.058 0.000 
The cervical cancer is one of the most prevalent cancer 
among woman 
87.2 80 89 88.6 86.7 11.288 0.08 
Most people with genital HPV infections are 
symptomatic. 
81.1 75.9 80.4 90.9 80 8.766 0.187 
Genital warts are caused by the same HPV types that 
cause cervical cancer. 
35.7 43.9 24.6 65.9 58.1 40.452 0.000 
HPV vaccine is available for both males and females. 71 73.6 70.2 72.1 65.5 6.575 0.362 
Sexually active adolescents should be tested for HPV 
before vaccination. 
26.2 22.2 31.1 13.6 24.1 1.952 0.924 
Men and women who have been diagnosed with HPV 
should not be given HPV vaccine. 
27.2 24.5 28 25 31 1.952 0.952 
  268 
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There was no statistically significant difference in the specialty of physicians who 269 
were concerned about the newness of the vaccine (p=0.01) but there was with regard to 270 
the age at which it should be given (p<0.0001). Family physicians were more concerned 271 
than other specialties that the vaccine was too new (74.5%; nearly double the rate recorded 272 
for oncologists at 36.70%) and that a 13-year-old was too young to receive the vaccine 273 
(54.5%; against an average across all specialties of 42.90%), suggesting that this speciality 274 
is more prone to vaccine hesitancy than others, the reasons for which require further 275 
investigation.  276 
Respondents who were concerned about efficacy were more likely to hold the 277 
opinion that the HPV vaccine is too new and “has not been around long enough” (58.8%) 278 
(Figure 2).  279 
The proportion of physicians over the age of 60 who were concerned that 13-year-old 280 
females were too young for the vaccination was higher (55.4%) than in younger physicians 281 
(39.2%), suggesting that attitudes can differ between demographic groups. The differences 282 
in answers to this question among the different age groups was statistically significant 283 
(p=0.003).  284 
In a final question, respondents reported that they had gained information about 285 
HPV vaccine from conferences and special events organized by the Ministry of Health, 286 
Armenia (72%), specialist literature (63%), colleagues (58%), and self-guided internet 287 
searches (57%). 288 
 289 
3.6. Practice of HPV vaccination amongst physicians in Yerevan 290 
No specific questions were asked regarding physicans’ practice in administering the 291 
vaccine or not to eligible patients, as information on practice is taken from figures on 292 
vaccination coverage in Armenia recorded by existing studies, which show that it is very 293 
low compared to other countries [1, 2, 6, 7, 8]. Our study sought to explore the reasons for 294 
this, which we assume are influenced by the knowledge and attitudes we discuss above. 295 
Not having recorded practice specifically is a limitation of the study we would seek to 296 
address in further investigations; in particular it would be valuable to investigate which 297 
specific attitudes influence the decisions of individual physicians to adminster or not 298 
administer the vaccine. 299 
 300 
4. Discussion 301 
Our study shows that there are knowledge gaps in the understanding of Armenian 302 
physicians with regards to some basic aspects of HPV infection and the HPV vaccine. 303 
These knowledge gaps affect physicians’ understanding of disease transmission; 304 
symptoms and presentation; who will benefit from the vaccine; and vaccine safety and 305 
efficacy. This is one of the first KAP (Knowledge, Attitudes and Practice) studies to be 306 
conducted with regard to physicians’ attitudes towards vaccination in Armenia and its 307 
results show that this is a complex area that requires much more nuanced understanding 308 
before interventions can be developed. It does, however, suggest that poor knowledge is 309 
influencing sub-optimal attitudes and practice. 310 
The level of understanding amongst Armenian physicians (their knowledge) with 311 
regard to the mechanisms of disease and vaccination efficacy [31] and benefits is poor. 312 
The majority of the physicians knew that cervical cancer is one of the most prevalent types 313 
of cancer among women and that it is caused by the HPV virus but only half of the 314 
participants knew that genital warts and cervical cancer are caused by different strains of 315 
HPV and one third were unaware that the HPV vaccine is available for both females and 316 
males. This suggests that better information about vaccine-controllable diseases and their 317 
aetiology may need to be provided as part of vaccination roll-out programmes to ensure 318 
that physicians are well-informed, and their knowledge is up to date.  319 
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The particularly low number of correct answers given by the longer-serving group 320 
(Table 1) suggests that continued professional training after qualification, to keep one’s 321 
skills up-to-date, may be lacking; although the least experienced group also scored lower 322 
than the group with mid-level experience. Further study is required to understand the 323 
reasons for this and there may be value in more systematically embedding awareness 324 
training as part of continuing professional development programmes for healthcare 325 
workers who are likely to be in roles that can influence vaccine take-up or hesitancy.  326 
Almost all respondents were aware of the HPV vaccine but their lack of knowledge 327 
impacts on their attitudes to its efficacy and safety, and thus its value to patients. 328 
Paediatricians were significantly more knowledgeable than other speciality groups, 329 
possibly because they were the group most likely to be dealing with the age group that is 330 
recommended for vaccination. However, the results show that knowing a vaccine is 331 
available does not always correspond to being willing to recommend it, particularly when 332 
one is not well informed about it or the disease it can prevent. 62% of physicians were 333 
concerned about side effects of the HPV vaccine (although they were not able to specify 334 
what any such side effects might be) suggesting that honest discussions around any likely 335 
side effects, including their frequency, treatment and patient outcomes may help to build 336 
healthcare practitioner confidence, change their attitudes towards the vaccines and enable 337 
them to pass this confidence on to patients, and thus inform their practice around vaccine 338 
administration. In addition, 54% of the physicians were worried about the effectiveness 339 
of the HPV vaccine, which again could be addressed by in-job training and awareness that 340 
would help them to change their attitudes towards the value of vaccination and impart 341 
greater confidence to patients, who are likely to look to healthcare professionals to advise 342 
them. 343 
It is concerning that knowledge gaps exist despite the fact that almost all respondents 344 
reported participating in special events, such as training and seminars, and mentioned 345 
specialized literature as one of their main sources of information. This suggests that the 346 
current training and methods of information dissemination are ineffective. Further studies 347 
are needed to understand the reasons behind these statistics as physicians can act as 348 
powerful gatekeepers to vaccines; their level of knowledge influences their attitudes 349 
which in turn influences their practice and thus has ramifications for vaccine hesitancy 350 
and acceptance (or not) within the communities of patients they attend. 351 
4.1. Cultural assumptions and misconceptions 352 
We note that cultural assumptions in particular influence attitudes and threaten to 353 
undermine the scientific basis of vaccine schedules. In Armenia, the routine early 354 
childhood immunisation coverage is estimated at 93%-97% of all children and physicians 355 
strongly support vaccination programmes amongst this age group [17]. Our study 356 
suggests that whilst early childhood vaccinations are strongly supported by most of the 357 
physicians surveyed (87.70%), attitudes are different towards the HPV vaccine: fewer are 358 
comfortable with the inclusion of the HPV vaccine into the national vaccination 359 
programme (63.80%). The physicians had a tendency to associate HPV vaccination with 360 
the onset of sexual activity and felt that support for the vaccination of young girls was a 361 
tacit acceptance of early sexual activity. This attitude was more frequently found among 362 
physicians over 60 years old, suggesting that vaccine hesitancy is more complex than a 363 
binary ‘yes/no’: a ‘no’ for one age cohort may become a ‘yes’ for another. Controversies 364 
among health professionals relating to the inclusion of HPV in national immunization 365 
schedules has also been described in Spain, where 89% of health professionals were aware 366 
of the relationship between HPV infection and cervical cancer but 65.7% resist its 367 
introduction into vaccine schedules, arguing that there is no data on its long-term 368 
effectiveness [28].  369 
However, the age of vaccine administration is not, in fact, determined by the age at 370 
which sexual activity is likely to begin: according to the WHO, the recommended priority 371 
age for HPV vaccination is 9-13 years old because this is the age at which the immune 372 
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system response is highest and produces the necessary level of antibodies and immune- 373 
system memory to protect against HPV infection for life, not because this is the age at 374 
which children may become sexually active. It is important for preteens to get all three 375 
doses long before any sexual activity begins [32]. This shows a direct link between level 376 
of knowledge and cultural attitudes and beliefs, which intersect with scientific evidence 377 
to build acceptance or resistance to vaccination. Vaccine confidence or hesitancy can be 378 
based on sociocultural factors as well as medical science and thus is it important to ensure 379 
attitudes based on incomplete knowledge, that can impede vaccination, are addressed 380 
through improving knowledge.  381 
The Armenian physicians expressed considerable concern over the newness of the 382 
Gardasil vaccine (from 36.7% amongst oncologists to 74.5% in family physicians; 58.5% 383 
across all specialities). This attitude may require targeted education to help healthcare 384 
providers understand the development and approvals process for these new vaccines in 385 
order to give assurance that these have been conducted safely [24] and thus give medical 386 
staff the confidence to reassure patients that new vaccines are safe. By paying more 387 
attention to how a disconnect between the scientific basis for the decision to vaccinate and 388 
the cultural assumptions against vaccination at this particular age influences physicans’ 389 
attitudes, we can start to explore how such attitudes can be changed. It also illustrates that 390 
by not being aware of such assumptions and failing to take time to address them in 391 
awareness information and training given to professionals responsible for administering 392 
the vaccine, vaccine confidence can be undermined by misconceptions and cultural 393 
perceptions that may prove harder to dispel later on, preventing the practice of 394 
appropriate vaccination.  395 
4.2. Vaccine hesitancy may not be universal 396 
The different levels of confidence in the national childhood vaccination programme 397 
compared with the introduction of the HPV vaccination highlight that individual vaccines 398 
need to be considered independently of one another as attitudes may differ between one 399 
vaccine and another, or one context and another. Vaccine hesitancy may not be universal 400 
to all vaccines nor have the same underlying concerns with regard to each vaccine. 401 
Understanding these attitudes more fully would benefit from further research to help 402 
determine how different forms of hesitancy can be effectively challenged, how they 403 
influence and impact on practice, and what steps might be taken in advance to stop such 404 
hesitancy from becoming widespread within certain communities. Refusal of one vaccine 405 
does not necessarily point to complete vaccine denial.  406 
 407 
Whilst we appreciate that HPV and Gardasil are one specific case, we do believe that 408 
the above findings highlight issues that are likely to be generalizable to other vaccines and 409 
to be transferable to attitudes towards vaccines more widely than the Gardasil vaccine 410 
and HPV alone. Firstly, they identify a spectrum of vaccine hesitancy [33] in which vaccine 411 
acceptance or refusal is not absolute but dependent on complex factors that may be unique 412 
to the time, context and even the individual physician, for example, the newness of the 413 
vaccine; the age of the patient to whom it is due to be administered; and misconceptions 414 
about the vaccine’s purpose amongst healthcare workers. Awareness of this complexity 415 
is also likely to be needed to inform vaccination strategies for COVID-19, another vaccine 416 
for which high levels of hesitancy have been observed in Armenia, some also linked to the 417 
newness of the vaccine in particular. As of 24 May, 2021 only 26,562 COVID-19 vaccines 418 
had been administered in the country, covering just 0.8% of the population, although 419 
vaccine doses were readily available [34]. Despite the widespread and growing 420 
prevalence of COVID-19 in Armenia, a nationwide poll by the International Republican 421 
Institute’s (IRI) Centre for Insights in Survey Research, published on 28 May 2021, 422 
recorded that 71% of Armenians (75% in Yerevan) would not get vaccinated against 423 
COVID-19 if vaccines were made available [7], whilst a different survey, conducted by 424 
Gallup International in April 2021 [8], also put vaccine hesitancy at above 51.9%, with the 425 
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exact rate differing considerably between the UK-developed AstraZenca (9.2%) and 426 
Russian-developed Sputnik V (75.8%) vaccines. The vaccines for COVID-19 are, like those 427 
for HPV, new: the Armenian physicians who expressed concern over the newness of the 428 
Gardasil vaccine (from 36.7% amongst oncologists to 74.5% in family physicians; 58.5% 429 
across all specialities) may well also be concerned about vaccines for COVID-19, which 430 
are not only new but have been developed more quickly than is usual. Secondly, though 431 
linked to the first point, as with the HPV vaccine, Armenians who are generally accepting 432 
of most vaccines can have concerns over others, meaning that a population that is highly- 433 
vaccinated against existing diseases may not automatically be receptive to public health 434 
messaging campaigns for others: only 13% of Armenians who reported they would not 435 
take a COVID-19 vaccine claimed they do not get vaccines in general [7]. Both these points 436 
suggest that there is considerable room for confidence building around newly introduced 437 
vaccines, but that this will be more difficult if medical staff, to whom patients look for 438 
information, are also hesitant. We must be careful, however, in assuming that findings 439 
from a KAP study on one vaccine can be applicable to another, and thus how the findings 440 
from this study relate to confidence (or not) in other vaccines must be examined further. 441 
We present this as a basis from which further investigation should begin. 442 
Further studies could also usefully determine the extent to which physicians’ poor 443 
understanding, misconceptions and hesitancy may influence their decision to administer 444 
vaccines and their ability to sufficiently inform patients of vaccine benefits. 445 
4.3 Limitations 446 
Our study is represented by health facilities (and physicians) from Yerevan only, for 447 
a single vaccine, and during a specific period of time. Therefore, the findings may not be 448 
generalizable to the whole of Armenia, or to physicians in other countries, or to different 449 
vaccination programmes. Knowledge, attitudes, and practice of respondents working in 450 
medical facilities located out of Yerevan, and with different vaccines, may vary from study 451 
results. The assumptions we made about the generalisability of these findings to vaccine 452 
confidence in general are assumptions only and need to be tested in further research 453 
studies.  454 
5. Conclusion 455 
This study shows that the concerns and worries that influence negative attitudes 456 
towards vaccines, and which may prevent physicians from recommending vaccination, 457 
are complex. Reasons may differ for different diseases and may be influenced by different 458 
underlying factors, all of which suggest the need for stronger vaccine-confidence 459 
awareness training that helps physicians – and, by extension, the patients they advise – to 460 
navigate these concerns by providing up-to-date and comprehensive information that will 461 
enhance confidence and dispel unwarranted concerns. The surveyed healthcare workers 462 
were generally not hesitant to the concept of vaccines in general, more to uncertainties 463 
about aspects of vaccine development, efficacy or side effects that can be answered with 464 
easier access to accurate and up-to-date information. The role of the media, and its 465 
portrayal of vaccination development, may also have some influence in this process and 466 
should be considered within future research programmes.  467 
Differences in the approach of different physicians in Armenia to HPV vaccination 468 
was evident in this study, with different approaches noted based on their age, length of 469 
service, specialty and cultural assumptions. Overall, however, the study merely highlights 470 
gaps in our understanding of vaccine hesitancy and how this may vary between different 471 
vaccines and for the prevention of different diseases; it does not address them or offer 472 
interventions. In this regard, priority consideration should be given to further studying 473 
and, in the short term, to developing a programme of continuous education for Armenian 474 
healthcare professionals on all aspects of vaccination development, safety, efficacy and 475 
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societal value, both for HPV infections and for other newly developed vaccines, and not 476 
taking such knowledge for granted when introducing new vaccines. 477 
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